Special Issue "Novel BoNTs and Toxin Engineering"
Deadline for manuscript submissions: closed (31 May 2018)
Dr. Sabine Pellett
UW-Madison, Department of Bacteriology, Madison, WI 53706, USA
Botulinum Neurotoxins (BoNTs), the causative agents of the potentially lethal vertebrate disease botulism, comprise a large and expanding family of protein toxins produced by various bacterial strains of the genus Clostridium. BoNTs are significant as disease-causing agents, potential bioterrorist agents, and as unique, long-lasting, and widely used bio-pharmaceuticals. Currently, BoNTs are categorized into seven immunologically distinct serotypes with several subtypes within each serotype. However, in recent years, discoveries of novel BoNTs, as well as potential BoNT homologues in other organisms, have challenged this categorization and expanded the family of BoNTs. While novel BoNTs are continually being identified by sequencing, most have not been purified and functionally characterized. Further identification and characterizations of novel and known BoNTs will yield insight into the evolutionary forces driving the diversity of this protein toxin family and potentially reveal as yet unknown pharmacologic properties of BoNTs, with the potential to lead to novel or improved BoNT based bio-pharmaceuticals. Furthermore, genetic methods now allow for construction of recombinant and chimeric BoNTs, enabling directed engineering of BoNTs with defined amino acid or functional domain substitutions. Combined with ongoing structural analyses, these studies will lead to a deeper understanding of the molecular mechanisms underlying the toxicity and pharmacologic potential of the large family of BoNTs. Both approaches, exploring novel BoNTs and recombinant studies, are exciting avenues of research with the potential to open the doors to unlocking the underlying molecular and evolutionary mechanisms of the high potency of BoNTs, eventually leading to improved safety approaches, countermeasures development, and novel pharmaceuticals and pharmaceutical applications.
Dr. Sabine Pellett
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Botulinum Neurotoxin
- Clostridium botulinum